AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15056196 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects labeled with different nouns
Number of subjects: 123
Study 11342725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5% 10 ml, 50 mg) injected into cannula sites before incisions and 10 ml diluted with 100 ml saline into the peritoneal cavity at completion of the procedure
Number of subjects: 150
Study 11342725 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (equal amount used in controls)
Number of subjects: 150
Study 11342725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 150
Study 11342725 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 150
Study 9146812 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 200 mg biweekly for 6 weeks
Number of subjects: 0
Study 9146812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7962369 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maternal serum from smoking women
Number of subjects: 0
Study 7962369 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maternal serum from non-smoking women
Number of subjects: 0
Study 7962369 — intervention group
Group type: COMPARATOR
Intervention: 2% maternal serum (control)
Number of subjects: 0
Study 7962369 — intervention group
Group type: COMPARATOR
Intervention: 10% male serum (control)
Number of subjects: 0
Study 2890365 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg kg‐1) without priming dose (Group 1)
Number of subjects: 50
Study 2890365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.09 mg kg‐1) with priming dose of 0.015 mg kg‐1 (Group 2)
Number of subjects: 50
Study 2890365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.085 mg kg‐1) with priming dose of 0.02 mg kg‐1 (Group 3)
Number of subjects: 50
Study 2890365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.08 mg kg‐1) with priming dose of 0.02 mg kg‐1 (Group 4)
Number of subjects: 50
Study 2890365 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium (1.5 mg kg‐1) (Group 5)
Number of subjects: 50
Study 29436761 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg qd (G2)
Number of subjects: 335
Study 29436761 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin 25 mg bid to 50 mg qd (G1/G2)
Number of subjects: 335
Study 29436761 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg qd to gemigliptin 50 mg qd (S/G2)
Number of subjects: 335
Study 29436761 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg qd (G2/G2)
Number of subjects: 335
Study 27220310 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization + Best Medical Therapy (BMT)
Number of subjects: 0
Study 27220310 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Therapy (BMT)
Number of subjects: 0
Study 23447453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Exercise Training (HIT), n=20
Number of subjects: 43
Study 23447453 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Aerobic Exercise Training (LIT), n=23
Number of subjects: 43
Study 23830536 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 15
Study 23830536 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment only)
Number of subjects: 15
Study 20117319 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based guidelines for diagnosis and treatment of CTS
Number of subjects: 0
Study 18377249 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation (MCS)
Number of subjects: 11
Study 18377249 — intervention group
Group type: COMPARATOR
Intervention: Motor cortex stimulation (MCS) OFF mode
Number of subjects: 11
Study 16482075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod protein meal
Number of subjects: 17
Study 16482075 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein meal
Number of subjects: 17
Study 14563967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal urokinase infusion (ITUKI therapy)
Number of subjects: 110
Study 14563967 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 110
Study 11149069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral outpatient chronic pain management program
Number of subjects: 61
Study 9082657 — intervention group
Group type: EXPERIMENTAL
Intervention: customary fat-reduced foods (D group)
Number of subjects: 70
Study 9082657 — intervention group
Group type: COMPARATOR
Intervention: products with normal fat content (K group)
Number of subjects: 70
Study 1615478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofil M
Number of subjects: 5
Study 1615478 — intervention group
Group type: COMPARATOR
Intervention: Hemofil CT (control)
Number of subjects: 5
Study 370160 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD
Number of subjects: 7
Study 370160 — intervention group
Group type: EXPERIMENTAL
Intervention: DA
Number of subjects: 7
Study 370160 — intervention group
Group type: COMPARATOR
Intervention: PL
Number of subjects: 7
Study 31608799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg bid
Number of subjects: 20
Study 31608799 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 5 mg od
Number of subjects: 20
Study 30511291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Primary Care (MTPC) - an 8-week program integrated into primary care.
Number of subjects: 136
Study 30511291 — intervention group
Group type: COMPARATOR
Intervention: Low-Dose Comparator (LDC) - a 60-min mindfulness introduction, referral to community and digital resources, and addition to a 6-month waitlist for MTPC.
Number of subjects: 136
Study 28881303 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based parenting program
Number of subjects: 68
Study 28881303 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 68
Study 26115069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering treatment with 80 mg rosuvastatin loading followed by 40 mg daily
Number of subjects: 140
Study 26115069 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (standard statin therapy according to current guidelines)
Number of subjects: 140
Study 23551788 — intervention group
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy
Number of subjects: 1071
Study 23551788 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance processes
Number of subjects: 1071
Study 23551788 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic audit feedback
Number of subjects: 1071
Study 22043972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass S53P4 (BAG)
Number of subjects: 29
Study 22043972 — intervention group
Group type: COMPARATOR
Intervention: Autograft bone (AB)
Number of subjects: 29
Study 22043972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BAG and AB)
Number of subjects: 29
Study 18991182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 167
Study 18991182 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethizole
Number of subjects: 167
Study 16202192 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN) point prevalence in women
Number of subjects: 2491
Study 16202192 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Disorder Inventory Bulimia scores
Number of subjects: 2491
Study 15719746 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhitiaokang capsule (ZTK) for 8 weeks
Number of subjects: 186
Study 15719746 — intervention group
Group type: COMPARATOR
Intervention: Zhibituo tablet (Control) for 8 weeks
Number of subjects: 186
Study 12952517 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of stretching with a 30 Nm torque at the hip, each weekday for four weeks
Number of subjects: 16
Study 12952517 — intervention group
Group type: COMPARATOR
Intervention: No stretching (control condition)
Number of subjects: 16
Study 10459516 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosalpinx group
Number of subjects: 1000
Study 10459516 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1000
Study 8541097 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive, self‐measured procedure using a thermometric brassiere for 90 min each evening
Number of subjects: 91
Study 8541097 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiles of progesterone through the cycle obtained from daily saliva sampling
Number of subjects: 91
Study 2172371 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine at a dose of 4 micrograms/kg per min (Control)
Number of subjects: 21
Study 2172371 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat at a dose of 1 microgram/kg per min
Number of subjects: 21
Study 2172371 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat at a dose of 2.5 micrograms/kg per min
Number of subjects: 21
Study 422029 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane (cyproteronazetate 2 mg, ethinyloestradiol 50 mcg)
Number of subjects: 10
Study 422029 — intervention group
Group type: EXPERIMENTAL
Intervention: Neogynon (D‐Norgestrel 0.25 mg, ethinyloestradiol 50 mcg)
Number of subjects: 10
Study 422029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyndiol (Lynestrenol 2.5 mg with ethinyloestradiol 50 mcg)
Number of subjects: 10
Study 29461074 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term memory (STM) content
Number of subjects: 0
Study 29461074 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational models of visual attention
Number of subjects: 0
Study 26260780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination-focused cognitive behaviour therapy
Number of subjects: 128
Study 26260780 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy
Number of subjects: 128
Study 23648055 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 112
Study 23648055 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-posture positioning (SPP)
Number of subjects: 112
Study 23648055 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 21936344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (3 x 12.5 mg daily)
Number of subjects: 60
Study 21936344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18421047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/m2/d)
Number of subjects: 214
Study 18421047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/m2/d) in low-risk arm
Number of subjects: 214
Study 18421047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/m2/d) in standard/high-risk arm
Number of subjects: 214
Study 18421047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone pharmacokinetics
Number of subjects: 214
Study 16025957 — intervention group
Group type: EXPERIMENTAL
Intervention: Danning Tablet (DNT)
Number of subjects: 135
Study 16025957 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 135
Study 12660056 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (3-month multicomponent intervention led by a non-medical health worker including psychoeducational group intervention, structured follow-up, and drug treatment for severe depression)
Number of subjects: 240
Study 12660056 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 11512206 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent AIDS education program (specialized program)
Number of subjects: 410
Study 11512206 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent AIDS education program (traditional program)
Number of subjects: 410
Study 11512206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AIDS education programs
Number of subjects: 410
Study 8551753 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated perfusion circuits (Carmeda process; Medtronic Cardiopulmonary)
Number of subjects: 20
Study 8551753 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic heparin (300 U/kg)
Number of subjects: 20
Study 8551753 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits
Number of subjects: 20
Study 1867303 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin 1% suspension
Number of subjects: 50
Study 1867303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1867303 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin 1% suspension (after placebo)
Number of subjects: 50
Study 7068283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg administered thrice daily
Number of subjects: 50
Study 7068283 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin administered thrice daily
Number of subjects: 50
Study 30191395 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy with a written checklist for parents to fully complete (Group II)
Number of subjects: 79
Study 30191395 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy as a written guideline (Group I)
Number of subjects: 79
Study 30191395 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin treatment plus verbal behavioural therapy (Group III)
Number of subjects: 79
Study 27714892 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Health scale for older adults (PIH-OA)
Number of subjects: 1127
Study 26467797 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Glasgow prognostic score = 2
Number of subjects: 968
Study 26467797 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CA19‐9 ≥300 U/ml
Number of subjects: 968
Study 26467797 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size ≥30 mm
Number of subjects: 968
Study 26467797 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 1 and ≥2 risk factors in R-PDAC patients
Number of subjects: 968
Study 24124036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour intervention (SB-I)
Number of subjects: 268
Study 24124036 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (PA-I)
Number of subjects: 268
Study 24124036 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PA+SB intervention
Number of subjects: 268
Study 24124036 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study 22946861 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous thermoradiotherapy with hyperthermia
Number of subjects: 57
Study 22946861 — intervention group
Group type: COMPARATOR
Intervention: Control sectors (unheated)
Number of subjects: 57
Study 18555556 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epirubicin/cisplatin
Number of subjects: 64
Study 17697201 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg q.d.s.
Number of subjects: 1541
Study 17697201 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg b.d.
Number of subjects: 1541
Study 17697201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1541
Study 17697201 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 or 80 mg)
Number of subjects: 1541
Study 17697201 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 1541
Study 15161458 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal lower-body muscle power assessed using vertical jump height (VJH)
Number of subjects: 78
Study 15161458 — intervention group
Group type: EXPERIMENTAL
Intervention: High thigh muscle density
Number of subjects: 78
Study 15161458 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative area occupied by the fastest muscle fiber types (IIax+IIx)
Number of subjects: 78
Study 15161458 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric knee extension strength (KES)
Number of subjects: 78
Study 15161458 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body fat mass
Number of subjects: 78
Study 11201904 — intervention group
Group type: EXPERIMENTAL
Intervention: Community behaviour towards persons affected by leprosy
Number of subjects: 100
Study 11201904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of infection and fear of a curse from God
Number of subjects: 100
Study 11201904 — intervention group
Group type: EXPERIMENTAL
Intervention: Leprosy control programmes
Number of subjects: 100
Study 9380806 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Hemodialysis
Number of subjects: 31
Study 9380806 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 31
Study 9380806 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Age-Matched Subjects)
Number of subjects: 31
Study 8328192 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (100 mg in 90 min)
Number of subjects: 421
Study 8328192 — intervention group
Group type: COMPARATOR
Intervention: APSAC
Number of subjects: 421
Study 8328192 — intervention group
Group type: EXPERIMENTAL
Intervention: r-PA (10 MU)
Number of subjects: 421
Study 8328192 — intervention group
Group type: EXPERIMENTAL
Intervention: r-PA (15 MU)
Number of subjects: 421
Study 3524225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafcillin for two weeks
Number of subjects: 84
Study 3524225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafcillin for four weeks
Number of subjects: 84
Study 3524225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafcillin for six weeks
Number of subjects: 84
Study 3524225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafcillin for four or six weeks
Number of subjects: 84
Study 30646133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet, physical activity, behavior modification)
Number of subjects: 957
Study 30646133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard information about diet and exercise)
Number of subjects: 957
Study 26928413 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported medical errors
Number of subjects: 471
Study 26928413 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported preventable adverse events (AEs)
Number of subjects: 471
Study 26928413 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical data analysis
Number of subjects: 471
Study 26928413 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical record review
Number of subjects: 471
Study 25177814 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium (500 mg/day) for 3 months
Number of subjects: 56
Study 25177814 — intervention group
Group type: COMPARATOR
Intervention: Control group (no meldonium)
Number of subjects: 56
Study 21823980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (PUS) 1 MHz, 1:9 ratio, 0.5 W/cm2 for maxillary sinuses, 1 W/cm2 for frontal sinuses, 10 sessions, 3 days per week, every other day.
Number of subjects: 40
Study 21823980 — intervention group
Group type: COMPARATOR
Intervention: Continuous ultrasound (CUS) 1 MHz, 1:9 ratio, 0.5 W/cm2 for maxillary sinuses, 1 W/cm2 for frontal sinuses, 10 sessions, 3 days per week, every other day.
Number of subjects: 40
Study 21823980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (PUS)
Number of subjects: 40
Study 21823980 — intervention group
Group type: COMPARATOR
Intervention: Continuous ultrasound (CUS)
Number of subjects: 40
Study 21823980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 20350924 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 389
Study 20350924 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 389
Study 20350924 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine and Pioglitazone
Number of subjects: 389
Study 18597891 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-search condition with large amount of information
Number of subjects: 120
Study 18597891 — intervention group
Group type: EXPERIMENTAL
Intervention: Read-only condition with medium amount of information
Number of subjects: 120
Study 18597891 — intervention group
Group type: COMPARATOR
Intervention: Read-only condition with large amount of information
Number of subjects: 120
Study 16162049 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect linked to behavioral goals
Number of subjects: 0
Study 16162049 — intervention group
Group type: COMPARATOR
Intervention: Neutral or negative affect linked to behavioral goals
Number of subjects: 0
Study 12660281 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 166
Study 12660281 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation
Number of subjects: 166
Study 10366369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins
Number of subjects: 11
Study 7483804 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal group B (15:P1.3) outer membrane protein vaccine, two doses six weeks apart
Number of subjects: 40811
Study 7483804 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal group B (15:P1.3) outer membrane protein vaccine
Number of subjects: 40811
Study 7483804 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Menomune, A, C, Y and W135 meningococcal polysaccharide vaccine)
Number of subjects: 40811
Study 2278224 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin (0.2 mg/kg at 24th, 36th, and 60th hour of age)
Number of subjects: 32
Study 2278224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 ml 0.33% saline in 5% G/W solution at the same schedule)
Number of subjects: 32
Study 7400476 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 15
Study 7400476 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 15
Study 7400476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Theophylline and Terbutaline
Number of subjects: 15
Study 7400476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29723441 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone extended-release (ER) 45 mg
Number of subjects: 2
Study 29723441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of finely milled hydrocodone ER, hydrocodone powder, and finely milled Zohydro® ER
Number of subjects: 2